1. Home
  2. ALT vs LYTS Comparison

ALT vs LYTS Comparison

Compare ALT & LYTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • LYTS
  • Stock Information
  • Founded
  • ALT 1997
  • LYTS 1976
  • Country
  • ALT United States
  • LYTS United States
  • Employees
  • ALT N/A
  • LYTS N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • LYTS Building Products
  • Sector
  • ALT Health Care
  • LYTS Consumer Discretionary
  • Exchange
  • ALT Nasdaq
  • LYTS Nasdaq
  • Market Cap
  • ALT 327.4M
  • LYTS 549.1M
  • IPO Year
  • ALT N/A
  • LYTS N/A
  • Fundamental
  • Price
  • ALT $3.59
  • LYTS $22.97
  • Analyst Decision
  • ALT Strong Buy
  • LYTS Strong Buy
  • Analyst Count
  • ALT 6
  • LYTS 2
  • Target Price
  • ALT $17.40
  • LYTS $27.50
  • AVG Volume (30 Days)
  • ALT 2.5M
  • LYTS 252.5K
  • Earning Date
  • ALT 11-11-2025
  • LYTS 11-06-2025
  • Dividend Yield
  • ALT N/A
  • LYTS 0.88%
  • EPS Growth
  • ALT N/A
  • LYTS N/A
  • EPS
  • ALT N/A
  • LYTS 0.79
  • Revenue
  • ALT $20,000.00
  • LYTS $573,377,000.00
  • Revenue This Year
  • ALT N/A
  • LYTS $6.88
  • Revenue Next Year
  • ALT $761,880.20
  • LYTS $6.95
  • P/E Ratio
  • ALT N/A
  • LYTS $28.92
  • Revenue Growth
  • ALT N/A
  • LYTS 22.09
  • 52 Week Low
  • ALT $2.90
  • LYTS $13.77
  • 52 Week High
  • ALT $11.16
  • LYTS $25.50
  • Technical
  • Relative Strength Index (RSI)
  • ALT 44.54
  • LYTS 61.57
  • Support Level
  • ALT $3.60
  • LYTS $22.32
  • Resistance Level
  • ALT $3.82
  • LYTS $23.89
  • Average True Range (ATR)
  • ALT 0.17
  • LYTS 0.73
  • MACD
  • ALT 0.02
  • LYTS -0.15
  • Stochastic Oscillator
  • ALT 47.52
  • LYTS 53.77

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About LYTS LSI Industries Inc.

LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Lighting segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays and custom display elements.

Share on Social Networks: